doxazosin has been researched along with Erectile Dysfunction in 22 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Erectile Dysfunction: The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 9.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 9.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction." | 9.13 | Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Chan, ES; Cheng, CW; Hou, SM; Ng, CF; Wong, A; Wong, HM, 2008) |
| "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH." | 9.11 | Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. ( Carson, C; Kirby, RS; O'Leary, MP, 2005) |
| "The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil." | 9.10 | Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. ( Carmignani, G; De Rose, AF; Giglio, M; Lantieri, P; Traverso, P, 2002) |
| "Doxazosin mesylate is an alpha1-adrenoceptor antagonist that was used to treat hypertension until a major study (ALLHAT; Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) showed that it increased the risk of progressing to heart failure." | 6.42 | After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 6.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 5.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "Doxazosin was given for 30 days, and at the second visit IPSS, NIH-CPSI and IIEF-5 scores, Qmax and PMR were once more analysed." | 5.37 | Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms. ( Aktas, A; Eryildirim, B; Faydaci, G; Kuyumcuoglu, U; Tarhan, F; Tuncer, M, 2011) |
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 5.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline." | 5.14 | The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. ( Aslan, G; Bozkurt, O; Demir, O; Esen, AA; Ozdemir, I, 2009) |
| "We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction." | 5.13 | Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. ( Chan, ES; Cheng, CW; Hou, SM; Ng, CF; Wong, A; Wong, HM, 2008) |
| "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH." | 5.11 | Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. ( Carson, C; Kirby, RS; O'Leary, MP, 2005) |
| "The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil." | 5.10 | Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. ( Carmignani, G; De Rose, AF; Giglio, M; Lantieri, P; Traverso, P, 2002) |
| "Thirty-eight consecutive men with moderate to severe erectile dysfunction on the basis of history and examination and with minimal or no therapeutic response to intracavernosal alprostadil injection therapy were evaluated." | 5.08 | Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. ( Kaplan, SA; Kohn, IJ; Reis, RB; Shabsigh, R; Te, AE, 1998) |
| "alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension." | 4.83 | Effects of alpha(1)-adrenoceptor antagonists on male sexual function. ( de la Rosette, JJ; Michel, MC; van Dijk, MM, 2006) |
| "An open, non-comparative, multicenter study was performed to ascertain the prevalence in Spain of erectile dysfunction (ED) associated to benign prostatic hypertrophy (BPH), with moderate to severe urinary symptoms, and to confirm the improvement or disappearance of ED in response to treatment with 4 mg/day of Doxazosin." | 3.72 | [Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study]. ( Castaño González, I; Hernández Fernández, C; Jara Rascón, J; Moncada Iribarren, I; Moralejo Gárate, M, 2004) |
| "The prevalence of benign prostatic hypertrophy (BPH) and erectile dysfunction (ED) both increase with age, and increasing evidence suggests a common cause rather than independent age-related changes." | 2.43 | Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. ( DE Rose, AF; Kaplan, SA; Kirby, RS; McVary, KT; O'leary, MP, 2006) |
| "Doxazosin mesylate is an alpha1-adrenoceptor antagonist that was used to treat hypertension until a major study (ALLHAT; Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial) showed that it increased the risk of progressing to heart failure." | 2.42 | After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 2.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "The drugs used to treat hypertension may cause ED." | 2.41 | The treatment of hypertension in patients with erectile dysfunction. ( Khan, MA; Mikhailidis, DP; Milionis, HJ; Morgan, RJ, 2000) |
| "Doxazosin was given for 30 days, and at the second visit IPSS, NIH-CPSI and IIEF-5 scores, Qmax and PMR were once more analysed." | 1.37 | Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms. ( Aktas, A; Eryildirim, B; Faydaci, G; Kuyumcuoglu, U; Tarhan, F; Tuncer, M, 2011) |
| "Doxazosin and Y-27632 generate effective CCSM relaxation in the presence of BOO." | 1.33 | Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. ( Aslan, G; Demir, O; Esen, AA; Gidener, S; Murat, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 16 (72.73) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Elbaz, R | 1 |
| El-Assmy, A | 1 |
| Zahran, MH | 1 |
| Hashem, A | 1 |
| Shokeir, AA | 1 |
| Roehrborn, CG | 1 |
| Rukstalis, DB | 1 |
| Andersson, KE | 1 |
| Ng, CF | 1 |
| Wong, A | 1 |
| Cheng, CW | 1 |
| Chan, ES | 1 |
| Wong, HM | 1 |
| Hou, SM | 1 |
| Oger, S | 1 |
| Behr-Roussel, D | 1 |
| Gorny, D | 1 |
| Lecoz, O | 1 |
| Lebret, T | 1 |
| Denoux, Y | 1 |
| Faix, A | 1 |
| Leriche, A | 1 |
| Wayman, C | 1 |
| Alexandre, L | 1 |
| Giuliano, F | 1 |
| Demir, O | 2 |
| Ozdemir, I | 1 |
| Bozkurt, O | 1 |
| Aslan, G | 2 |
| Esen, AA | 2 |
| Faydaci, G | 1 |
| Kuyumcuoglu, U | 1 |
| Eryildirim, B | 1 |
| Aktas, A | 1 |
| Tarhan, F | 1 |
| Tuncer, M | 1 |
| Jin, Z | 1 |
| Zhang, ZC | 1 |
| Liu, JH | 1 |
| Lu, J | 1 |
| Tang, YX | 1 |
| Sun, XZ | 1 |
| Song, WD | 1 |
| Gao, B | 1 |
| Guo, YL | 1 |
| Xin, ZC | 1 |
| Flack, JM | 1 |
| Hernández Fernández, C | 1 |
| Moncada Iribarren, I | 1 |
| Jara Rascón, J | 1 |
| Castaño González, I | 1 |
| Moralejo Gárate, M | 1 |
| Doggrell, SA | 1 |
| Kirby, RS | 2 |
| O'Leary, MP | 3 |
| Carson, C | 1 |
| Wyllie, MG | 1 |
| Kaplan, SA | 2 |
| DE Rose, AF | 2 |
| McVary, KT | 1 |
| van Dijk, MM | 1 |
| de la Rosette, JJ | 1 |
| Michel, MC | 1 |
| Murat, N | 1 |
| Gidener, S | 1 |
| Reis, RB | 1 |
| Kohn, IJ | 1 |
| Shabsigh, R | 1 |
| Te, AE | 1 |
| Papadakis, JA | 1 |
| Mikhailidis, DP | 3 |
| Khan, MA | 2 |
| Milionis, HJ | 1 |
| Morgan, RJ | 2 |
| Giglio, M | 1 |
| Traverso, P | 1 |
| Lantieri, P | 1 |
| Carmignani, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Multicenter Open-label One Arm Trial Investigating a Pumpkin Seed, Isoflavonoid and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia[NCT04146103] | 163 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for doxazosin and Erectile Dysfunction
| Article | Year |
|---|---|
The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Mid | 2002 |
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Dru | 2004 |
One drug fits all.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Drug Industry; Drug Therapy, Combination | 2005 |
Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Doxazosin | 2006 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
The treatment of hypertension in patients with erectile dysfunction.
Topics: Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hypertensi | 2000 |
8 trials available for doxazosin and Erectile Dysfunction
| Article | Year |
|---|---|
Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Topics: Acetanilides; Doxazosin; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic | 2022 |
Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure; Cross-Over Studies; Double | 2008 |
Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Drug Combinations; Erectile Dysfunction; Humans; Mal | 2009 |
The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; Peni | 2009 |
An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Asian People; China; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; | 2011 |
Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Met | 2005 |
Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Alprostadil; Doxazosin; Drug Therap | 1998 |
Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy.
Topics: Adult; Doxazosin; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Pipera | 2002 |
7 other studies available for doxazosin and Erectile Dysfunction
| Article | Year |
|---|---|
Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia.
Topics: Doxazosin; Erectile Dysfunction; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia | 2022 |
How many drugs for LUTS due to BPH are too many?
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; E | 2008 |
Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; | 2011 |
[Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Erectile Dysfunction; Human | 2004 |
Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Amides; Dose-Response Relationship, Drug; Doxazosin; Erectile Dy | 2006 |
Benign prostatic hyperplasia and hypertension.
Topics: Antihypertensive Agents; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Prostatic Hype | 1998 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |